The effectiveness of secretin in the management of autism

Bibliography

• FILIPEK PA, ACCARDO PJ, BARANEK GT et al.: The screening and diagnosis of autistic spectrum disorders. Autism Dev. Disord. (1999) 29(6):437–482.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th edit). Author, Washington, DC (1994).
   Google Scholar
• LORD C: Diagnostic instruments in autism spectrum disorders. In: Handbook of Autism and Pervasive Developmental Disorders (2nd edn). Cohen DJ, Volkmar FR (Eds), John Wiley & Sons, Inc., New York (1997):460–508.
   Google Scholar
• WING L: Syndromes of autism and atypical development. In: Handbook of Autism and Pervasive Developmental Disorders (2nd edn). Cohen DJ, Volkmar FR (Eds), John Wiley & Sons, Inc., New York (1997):148–170.
   Google Scholar
• GILLBERG C: Neurodevelopmental processes and psychological functioning in autism. Dev. Psychopathol (1999) 11(3):567–587.
   PubMedGoogle Scholar
• KERN JK: The possible role of the cerebellum in autism/PDD: disruption in a multisensory feedback loop. Med. Hypotheses (2002) 59(3):255–260.
   PubMedGoogle Scholar
• COURCHESNE E: New evidence of cerebellar and brain stem hypoplasia in autistic infants, children, and adolescents: the MR imaging study by Hashimoto and colleagues. Autism Dev. Disord. (1995) 25(1):19–22.
   PubMedGoogle Scholar
• WARREN RP, YONK J, BURGER RW, ODELL D, WARREN WL: DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology (1995) 31(2):53–57.
   PubMedGoogle Scholar
• HORVATH K, PAPADIMITRIOU JC, RABSZTYN A, DRACHENBERG C, TILDON JT: Gastrointestinal abnormalities In children with autistic disorder. Pediatrics (1999) 135(5):559–563.
   Google Scholar
• FURLANO RI, ANTHONY A, DAY R et al.: Colonic CD8 and 78T-cell infiltration with epithelial damage in children with autism. Pediatrics (2001)138(3):366–372.
   Google Scholar
• WARING RH, KLOVRZA LV: Sulphur metabolism in autism. Nuti: Environ. Med. (2000) 10:25–32.
   Google Scholar
• BOTTINI N, DE KUCA D,SACCUCCI P et al.: Autism: evidence of association with adenosine deaminase. Neurogenetics (2001) 3(2):111–113.
   Google Scholar
• KERN JK, MILLER VS, CAULLER LJ, KENDALL R, MEHTA J, DODD M: The effectiveness of N, N-dimethylglycine in autism/PDD. J. Child. Neurol (2001) 16(3):169–173.
   PubMedGoogle Scholar
• KERN JK, MILLER VS, EVANS PA, TRIVEDI MH: Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J. Autism Dev. Disord. (2002) 32(3):153–160.
   PubMedGoogle Scholar
• RUTTER M, BAILEY A, SIMONOFF E, PICKLES A: Genetic influences, and autism: In: Handbook of Autism and Pervasive Developmental Disorders (2'd edit). Cohen DJ, Volkmar FR (Eds), John Wiley & Sons, Inc., New York (1997):370–387.
   Google Scholar
• GILLBERG C: Chromosomal disorders and autism. I Autism Dev. Disord. (1998) 28(5):415–425.
   PubMedGoogle Scholar
• CHESS S: Follow-up report on autism in congenital rubella. J. Autism Dev. Disord. (1977) 7:68–81.
   Google Scholar
• BRYSON SE, CLARK BS, SMITH IM: First report of a Canadian epidemiological study of autistic syndromes. J. Child Psycho]. Psychiatry (1988) 29:433–446.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA T, ABE T: The prevalence of autism in Nagoya, Japan: a total population study. J. Autism Dev. Disord. (1989) 19:87–96.
   PubMed Web of Science ®Google Scholar
• WING L, GOULD J: Severe impairments of social interaction and associated abnormalities in children: epidemiological and classification. Autism Dev. Disord. (1979) 9:11–29.
   PubMed Web of Science ®Google Scholar
• BAIRD G, CHARMAN T, BARON-COHEN S et al: Screening a large population of 18 months olds with the CHAT. Paper presented at the Proceedings of the Society for Research on Child Development, Albuquerque, USA (1999).
   Google Scholar
• AMAN M, SINGH N: Aberrant Behavior Checklist. Slosson Educational Publications, Inc., New York (1986).
   Google Scholar
• SCHOPLER E, REICHLER RJ, RENNER BR: The Childhood Autism Rating Scale. Western Psychological Services, 12031 Wilshire Boulevard, Los Angeles, CA 90025–1251 (1994).
   Google Scholar
• LORD C, RUTTER M, DILAVORE PC, RISI S: Autism Diagnostic Observation Schedule. Western Psychological Services, 12031 Wilshire Blvd, Los Angeles, CA 90025–1251 (1999).
   Google Scholar
• LEITER R: International Performance Scale. IL, Stoefing, Chicago (1948).
   Google Scholar
• ZIMMERMAN I, STEINER V, POND R: Preschool Language Scale-3. The Psychological Corporation, San Antonio, TX (1992).
   Google Scholar
• LIGHTDALE JR, HAYER C, DUER A et al.: Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study. Pediatrics (2001) 108(5):E90.
   PubMedGoogle Scholar
• FENSON L, DALE PS, REZNICK JS et al.: MacArthur Communicative Development Inventories. Singular Publishing Group, Inc., London (1996).
   Google Scholar
• KRUG D, ARICK J, ALMOND P: Autism Behavior Checklist. Austin, TX: PRO-ED. (1980).
   Google Scholar
• SPARROWS, BALLAD, CICCHETTI D. Vineland Adaptive Behavior Scales. Circle Pines, MN, American Guidance Service (1994).
   Google Scholar
• YAMAGATA T, ARADHYA S, MORI M, INOUE K, MOMOI MY, NELSON DL: The human secretin gene: fine structure in 1 1 p15.5 and sequence variation in patients with autism. Genomics (2002)80(2):185–194.
   Google Scholar
• •No differences were found in the secretin gene of autistic individuals versus normal individuals.
   Google Scholar
• MITZNEGG P, BLOOM SR,DOMSCHKE W et al: Effect of secretin in plasma motilin in man. Gut (1977) 18:468–471.
   PubMedGoogle Scholar
• HORVATH K, STEFANATOS G, SOKOLSKI KN, WACHTEL R,aNAB ORS L, TILDON J: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Physicians (1998) 9:9–15.
   PubMedGoogle Scholar
• ••Caused a widespread interest in secretin asa treatment for autism.
   Google Scholar
• BANKS WA, GOULET M, RUSCHE JR, NIEHOFF ML, BOISMENU R: Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal flud barriers of the mouse. Pharmacol. Exp. The]: (2002) 302(3):1062–1069.
   PubMedGoogle Scholar
• ••Demonstrated that a secretin analogue can cross the blood-brain barrier.
   Google Scholar
• GOULET M, SHIROMANI PJ,WARE CM, STRONG RA,aBOISMENU R, RUSCHE JR: A secretin I.V. infusion activates gene expression in the central amygala of rats. Neuroscience (2003) 118:881–888.
   Google Scholar
• YUNG WH, LEUNG PS, NG SSM et al.: Secretin facilitates GABA transmission in the cerebellum. J. Neurosci. (2001) 21(18):7063–7068.
   PubMedGoogle Scholar
• COURCHESNE E: Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism. Curt: Opin. Neurobiol (1997) 7:269–278.
   PubMedGoogle Scholar
• RIVA D, GIORGI C: The cerebellum contributes to higher functions during development: evidence from a series of children surgically treated for posterior fossa tumors. Brain (2000) 123:1051–1061.
   PubMed Web of Science ®Google Scholar
• KOVES K, KAUSZ M, RESER D, HORVATH K: What may be the anatomical basis that secretin can improve the mental functions in autism? Regal. Pept. (2002) 15;109(1–3):167-72.
   Google Scholar
• NOZAKI S, NAKATA R, MIZUMA H et al.: In vitro autoradiographic localization of 125I-secretin receptor binding sites in rat brain. Biochem. Biophys. Res. Commun. (2002) 292:133–137.
   PubMedGoogle Scholar
• SANDLER AD, SUTTON KA, DEWEESE J, GIRARDI MA,SHEPARD V, BODFISH JW: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl. J. Med. (1999) 341(24):1801–1806.
   PubMedGoogle Scholar
• CHEZ MG, BUCHANAN CP, BAGAN BT et al.: Secretin and autism: aatwo part clinical investigation. Autism Dev. Disord. (2000) 30:87–94.
   PubMedGoogle Scholar
• DUNN-GEIER J, HO HH, AUESPERG Eet al.: Effect of secretin on children with autism: a randomized controlled trial. Dev. Med. Child Neurol (2000) 42:796–802.
   Google Scholar
• CONIGLIO SJ, LEWIS JD, LANG C et al.: A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin treatment for children with autism.aPediatr (2001) 138:649–655.
   Google Scholar
• LAMSON DW, PLAZA SM: Transdermal secretin for autism- a case report. Ahern. Med. Rev. (2001) 6:311–313.
   PubMedGoogle Scholar
• ROBERTS W, WEAVER L, BRIAN Jet al.: Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics (2001) 107(5):E71.
   Google Scholar
• •First clinical trial to use two secretin infusions.
   Google Scholar
• CORBETT B, KHAN K,CZAPANSKY-BEILMAN D et al: A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism. Clin. Pediatr. (2001) 40:327–331.
   PubMed Web of Science ®Google Scholar
• CAREY T, RATLIFF-SCHAUB K, FUNK J, WEINLE C, MYERS M, JENKS J: Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. I Autism Dev. Disord. (2002) 32(3):161–167.
   PubMedGoogle Scholar
• UNIS AS, MUNSON JA, ROGERS SJ et al.: A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. .1. Am. Acad. Child Adolesc. Psychiatry(2002) 44(11):1315–1321.
   Google Scholar
• •First clinical trial to study the efficacy of synthetic secretin versus porcine secretin.
   Google Scholar
• SPONHEIM E, OFTEDAL G, HELVESCHOU SB: Multiple doses of secretin in the treatment of autism: a controlled study. Acta. Paediatr. (2002) 91:540–545.
   PubMed Web of Science ®Google Scholar
• MOLLOY CA,MANNING-COURTNEY P, SWAYNE S et al.: Lack of benefit of intravenous synthetic human secretin in the treatment of autism. J. Autism Dev. Disord. (2002) 32(6):545–551.
   Google Scholar
• REPLIGEN CORPORATION: SecreFlo'" Clinical Trials. Repligen Corporation, Building 1, Suite 100, 41 Seyon Street, Waltham, MA 02453.
   Google Scholar
• LEVY SE, SOUDERS MC, WRAY J et al.:Children with autistic spectrum disorders. 1: comparison of placebo and single dose of human synthetic secretin. Arch. Dis. Child (2003) 88:731–736.
   Google Scholar
• http://www.autism.com/ari/dds/dds.html CALIFORNIA DEPARTMENT OF DEVELOPMENTAL SERVICES: Changes in the population of persons with autism and pervasive developmental disorders in california's developmental services system: 1987–1998, (1998)
   Google Scholar